RAVE: Switch Thymidine Analogue to ABC or TDF
{"Image DocumentName": "RAVE: Switch Thymidine Analogue to ABC or TDF", "Image ImageDescription": "Suppressed patients with self-defined lipoatrophy on thymidine analogue NRTI. 105 patients randomized to replace TA with. Tenofovir, or. Abacavir. Total limb fat increased to similar extent in both arms over 48 weeks. TDF ABC Change in Fat Mass by DEXA at Week 48 (g) ABC, abacavir; DEXA, dual energy x-ray absorptiometry; TA, thymidine analogue; TDF, tenofovir. The Randomized Abacavir Viread Evaluation (RAVE) study examined replacing a thymidine analogue with an alternative nucleoside or nucleotide analogue. In this study, patients with self-defined lipoatrophy were randomized to replace their thymidine analogue (stavudine or zidovudine) with either abacavir or tenofovir. Both strategies were associated with similar increases in total limb fat, with no significant differences between the treatment arms, suggesting that both abacavir and tenofovir are reasonable alternatives in patients with thymidine analogue\u2013associated fat loss. For more information, go online to: Limb. Trunk. Total Fat. Within-group change in limb fat from baseline: TDF (P = .01), ABC (P = .001) Moyle G, et al. CROI Abstract 44LB.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}